Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04280718 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT04280718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04280718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Lead sponsor
argenx
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 18, 2020
Completion date
April 30, 2027
Enrollment
229 (actual)
Sites
147

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyneuropathy (cidp)